Royal Bank Of Canada Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Moderate Buy
Royal Bank of Canada has upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to a "moderate buy" rating, aligning with a generally bullish analyst consensus. Despite recent insider selling pressure, with 25,003 shares sold last quarter, the company maintains an average price target of $131.50 from analysts. The stock traded down 3.3% to $99.75 on Wednesday, reflecting a market capitalization of $6.66 billion.
Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM)
Hunter Smith, CFO of Rhythm Pharmaceuticals Inc (RYTM), sold 7,954 shares on February 19, 2026, reducing his total holdings to 110,512 shares. This transaction is part of a trend of insider selling for the company, with 31 sells and no buys over the past year. The stock is currently deemed "Fairly Valued" based on its GF Value, trading at $101.31 against a GF Value of $97.09.
Rhythm pharmaceuticals CFO Smith sells $805k in shares
Hunter C. Smith, CFO of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 8,058 shares totaling approximately $805,813 in February 2026 under a Rule 10b5-1 plan. Despite a 79% stock increase over the past year, InvestingPro analysis suggests the shares are overvalued. The company, valued at $6.88 billion, is set to report earnings soon, following strong preliminary Q4 2025 revenues and recent positive analyst coverage.
Expert Outlook: Rhythm Pharmaceuticals Through The Eyes Of 11 Analysts
Eleven analysts have provided ratings for Rhythm Pharmaceuticals (NASDAQ: RYTM) over the last quarter, with a general sentiment ranging from bullish to somewhat bullish. The average 12-month price target has increased to $142.91, up 12.53% from the previous average. The company shows positive revenue growth of 54.28% and a strong net margin, although its market capitalization is below industry averages and ROE/ROA indicate challenges in capital and asset efficiency.
Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market
RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with an Outperform rating and a $145 price target, highlighting the company's leading position in the rare genetic obesity market. The analyst anticipates that Rhythm's drug Imcivree, following successful Phase 3 trials for hypothalamic obesity, could generate over $2 billion in revenue by 2030 by expanding its addressable market significantly. The company is also developing next-generation assets and researching setmelanotide for Prader-Willi Syndrome, further positioning it for future growth.
RBC Capital Initiates Coverage on Rhythm Pharmaceuticals With Outperform - Speculative Risk Rating, $145 Price Target
RBC Capital has initiated coverage on Rhythm Pharmaceuticals (RYTM) with an "Outperform - Speculative Risk" rating. The firm has set a price target of $145 for the biopharmaceutical company. This new coverage provides an analyst's perspective on the stock's potential, indicating a positive outlook with a recognition of inherent risks.
RBC Capital Initiates Coverage on RYTM with 'Outperform' Rating | RYTM Stock News
RBC Capital has initiated coverage on Rhythm Pharmaceuticals (RYTM) with an 'Outperform' rating and a price target of $145.00 USD. This follows several other analysts who have recently maintained or raised their ratings and price targets for RYTM. The average target price from 15 analysts is $139.47, indicating a potential upside of 39.24% from its current price, and the company is noted for its focus on developing therapies for rare diseases.
RBC Capital Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation
RBC Capital has initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform recommendation, setting a one-year price target of $142.26, suggesting a 40.43% upside from its last closing price. The company's projected annual revenue is 488MM, an increase of 180.19%, with an anticipated non-GAAP EPS of -2.95. Institutional ownership data shows 497 funds holding positions, with some major shifts in holdings among key investors like Ra Capital Management and Primecap Management.
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Zacks Research to Hold Rating
Zacks Research has upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) from a "strong sell" to a "hold" rating. Despite recent insider selling, institutional investors like RA Capital and Vanguard have significantly increased their stakes in the company, contributing to an overall "Moderate Buy" consensus from analysts with an average price target of $131.50. The company focuses on developing therapies for rare genetic diseases of obesity and metabolic dysfunction.
Readystate Asset Management LP Sells 16,301 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
Readystate Asset Management LP reduced its stake in Rhythm Pharmaceuticals (RYTM) by 66.1% in Q3, selling 16,301 shares and retaining 8,365 shares valued at $845,000. Company insiders have also sold shares totaling $1.78 million in the past 90 days. Analysts maintain a "Moderate Buy" consensus with an average target price of $131.50, despite recent insider selling and a slight stock decline.
Rhythm Pharmaceuticals (RYTM) to Release Quarterly Earnings on Wednesday
Rhythm Pharmaceuticals (RYTM) is scheduled to release its Q4 2025 earnings before market open on Wednesday, February 25th, with analysts expecting a loss of ($0.80) per share. The company's stock opened at $102.53, showing a 4.5% increase, and has a "Moderate Buy" consensus rating from Wall Street analysts with an average target price of $130.46. Recent insider activity includes sales by Pamela J. Cramer and Hunter C. Smith, while institutional investors have adjusted their stakes in RYTM.
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals, Inc. announced it will report its fourth-quarter and full-year 2025 financial results and provide a corporate update on a conference call and webcast on Thursday, February 26, 2026, at 8 a.m. ET. Additionally, the company's CEO, David Meeker, M.D., will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. ET. The article also provides detailed information about Rhythm's lead asset, IMCIVREE® (setmelanotide), its indications, limitations of use, contraindications, warnings, and adverse reactions.
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals, Inc. announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, via a live conference call and webcast. Additionally, David Meeker, M.D., Chair, President and CEO, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. The company, focused on rare neuroendocrine diseases, will provide a corporate update during the financial results call.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts
Rhythm Pharmaceuticals (NASDAQ:RYTM) has received a consensus "Moderate Buy" rating from eighteen research firms, with an average 12-month price target of $131.29. Despite this, company insiders have been net sellers, with the CFO and another executive selling over $1.78 million in shares recently. Rhythm Pharmaceuticals is a clinical-stage biotech focusing on rare genetic obesity, developing setmelanotide, an MC4R agonist.
Rhythm Pharmaceuticals Eyes March 20 HO PDUFA, Highlights IMCIVREE Growth at Guggenheim Conf.
Rhythm Pharmaceuticals is focused on an upcoming March 20 PDUFA date for hypothalamic obesity (HO), expanding its salesforce, and increasing the commercial traction of IMCIVREE for Bardet-Biedl syndrome, which already contributes around $57 million in sales. The company also highlighted a solid liquidity of $418 million cash, ensuring a 24-month runway, and an active pipeline including ongoing trials for Prader-Willi syndrome and development of new oral and injectable MC4R agonists.
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith Sells 1,592 Shares
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith recently sold 1,592 shares of the company's stock for approximately $156,382, reducing his ownership by 1.33%. The transaction comes as RYTM shares experienced a dip, trading down to $96.06 on higher than average volume, despite generally positive "Moderate Buy" ratings from Wall Street analysts with a consensus target price of $131.29.
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness
Rhythm Pharmaceuticals (RYTM) has experienced an 11% share price drop over the past month despite strong long-term returns, prompting a re-evaluation of its valuation. While a common narrative suggests the stock is undervalued at $141.57 due to potential regulatory approvals and revenue growth for IMCIVREE, its high Price/Sales ratio of 36.8x significantly exceeds industry averages. Investors are advised to consider both the growth potential and the high valuation metrics before making investment decisions.
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness
Rhythm Pharmaceuticals (RYTM) has experienced recent share price weakness, with an 11% drop over the past month, while still showing strong long-term returns. The company is considered undervalued by some analysts, with a fair value estimated at $141.57 due to potential regulatory approvals and revenue growth for its drug IMCIVREE. However, concerns exist regarding ongoing losses and a high P/S ratio compared to industry averages, prompting different valuation perspectives.
Hunter Smith Sells 2,713 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock
Hunter Smith, CFO of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 2,713 shares of the company's stock on February 10th for a total of $279,439, reducing his position by 2.16%. The stock traded down to $96.06 on Thursday on heavy volume, with a market cap of $6.41 billion and a negative P/E. Despite the insider sale, analyst sentiment remains mixed but generally positive, with a "Moderate Buy" consensus rating and an average target price of $131.29.
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $272,755.26 in Stock
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith sold 2,766 shares of the company's stock for $272,755.26, reducing his stake by 2.25%. The sale occurred on February 11th at an average price of $98.61 per share. Following the transaction, Smith now owns 120,058 shares valued at approximately $11.8 million, and the company maintains a "Moderate Buy" consensus rating from analysts with an average target price of $131.29.
Candriam S.C.A. Lowers Position in Rhythm Pharmaceuticals, Inc. $RYTM
Candriam S.C.A. decreased its stake in Rhythm Pharmaceuticals (NASDAQ:RYTM) by 29% in the third quarter, selling 90,589 shares but still holding 221,863 shares valued at approximately $22.4 million. Despite institutional selling, several analysts have raised their price targets for Rhythm Pharmaceuticals, maintaining a "Moderate Buy" consensus rating with an average target of $131.29. Company insiders, including CFO Hunter C. Smith, have also been net sellers of the stock, with 9,978 shares worth over $1 million sold last quarter.
Rhythm Pharmaceuticals prices $175M stock offering
Rhythm Pharmaceuticals has priced a stock offering aiming to raise $175 million. The offering includes 4,047,619 shares of common stock at $21.00 per share and 464,285 shares of its 8.50% Series A Convertible Preferred Stock at $100 per share. Proceeds will be used for general corporate purposes, including commercialization efforts for IMCIVREE, R&D, and working capital.
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock By Investing.com
Hunter C. Smith, CFO of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 6,628 shares of common stock for approximately $702,744 on February 4th and 5th, 2026, under a pre-arranged trading plan. Despite significant insider selling and notable stock price volatility, analysts maintain a bullish outlook for the biopharmaceutical company, which has seen its shares surge 75.08% over the past year. Rhythm Pharmaceuticals also reported strong preliminary unaudited Q4 2025 revenues, leading to positive adjustments in price targets from multiple firms.
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $344,149.53 in Stock
Rhythm Pharmaceuticals' CFO, Hunter Smith, sold 3,247 shares of RYTM stock for approximately $344,149.53 on February 4th. This transaction reduced his direct ownership by 2.46%, though he still holds a significant stake. The sale comes as Rhythm Pharmaceuticals reported an EPS miss but slightly better-than-expected revenue, with the stock trading around $103.61.
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock By Investing.com
Hunter C. Smith, CFO of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 6,628 shares of common stock for approximately $702,744 on February 4th and 5th, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sales, analysts maintain a bullish outlook on RYTM, with the company’s shares having surged 75.08% over the past year and recent positive preliminary Q4 2025 revenue results leading to raised price targets from several firms.
Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM)
Hunter Smith, CFO of Rhythm Pharmaceuticals Inc (RYTM), sold 6,628 shares of the company on February 5, 2026, and now holds 125,537 shares. The company, focused on rare genetic obesity disorders, has seen 42 insider sells and no insider buys in the past year. The stock was trading at $106.03, with a GF Value of $95.29, indicating it is considered fairly valued.
Penserra Capital Management LLC Acquires Shares of 30,436 Rhythm Pharmaceuticals, Inc. $RYTM
Penserra Capital Management LLC has acquired a new position of 30,436 shares in Rhythm Pharmaceuticals (NASDAQ:RYTM) during Q3, valued at approximately $3.07 million. This move is part of a broader trend of institutional accumulation, with other major firms like Federated Hermes, Westfield, Alkeon, and JPMorgan also increasing their stakes. Rhythm Pharmaceuticals, a clinical-stage biotech company with a market cap of $6.93 billion, currently holds a "Moderate Buy" analyst rating and a consensus price target of $131.29, despite recently missing quarterly EPS estimates.
Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by New York State Common Retirement Fund
New York State Common Retirement Fund has increased its stake in Rhythm Pharmaceuticals (NASDAQ:RYTM) by 28.2%, now owning 75,131 shares valued at approximately $7.59 million. Despite the company missing EPS expectations last quarter, analysts have a "Moderate Buy" rating with an average target price of $131.29, and some have significantly raised their price targets. Insider activity also shows a recent sale by an insider, reducing their ownership.
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
Rhythm Pharmaceuticals announced that its Chief Financial Officer, Hunter C. Smith, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11. The company, a commercial-stage biopharmaceutical firm, focuses on rare neuroendocrine diseases, with its lead asset IMCIVREE (setmelanotide) approved for treating hyperphagia and severe obesity in specific genetic conditions. The event will be webcasted and a replay will be available on the company's website.
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
Rhythm Pharmaceuticals, Inc. announced that its Chief Financial Officer, Hunter C. Smith, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The company is a commercial-stage biopharmaceutical firm focusing on rare neuroendocrine diseases, with its lead asset IMCIVREE® (setmelanotide) approved for specific genetic obesity conditions. The chat will be webcasted and available on the company's investor relations website.
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing
This article analyzes Rhythm Pharmaceuticals Inc. (RYTM) using AI models, outlining its impact on rotational strategy timing. It identifies a strong near-term sentiment potentially leading to mid-term neutrality and long-term positive bias, with an exceptional risk-reward setup. The analysis offers three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis and real-time AI-generated signals for traders.
WCM Investment Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM
WCM Investment Management LLC has made a new investment in Rhythm Pharmaceuticals (NASDAQ:RYTM), purchasing 47,733 shares valued at approximately $4.8 million during the third quarter. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $131.29, despite the company reporting a quarterly EPS miss and having negative margins. Insiders have also been selling shares, with one insider recently selling 3,350 shares.
This High-Flying Growth Stock Is Hiding in Plain Sight
Rhythm Pharmaceuticals (RYTM) is a biotech growth stock that has significantly outperformed major tech companies over the last year, despite its smaller size and focus on rare genetic obesity disorders. The company's lead drug, Imcivree, is awaiting FDA approval for an expanded indication and has multiple new clinical trial results expected, positioning it for potential further growth. However, risks include potential FDA setbacks, clinical study failures, and the company's current unprofitability.
Federated Hermes Inc. Has $174.50 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM
Federated Hermes Inc. increased its stake in Rhythm Pharmaceuticals (NASDAQ:RYTM) by 2.5% in the third quarter, bringing its total holding to 1,727,885 shares valued at approximately $174.5 million. The article also details other institutional investment changes, recent insider stock sales, and analyst ratings, which show a "Moderate Buy" consensus with an average price target of $131.29. Financial data indicates a market capitalization of $7.04 billion and recent quarterly earnings that missed analyst expectations.
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $145
BofA Securities analyst Tazeen Ahmad has reaffirmed a Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained a target price of $145. According to TipRanks data, the analyst has a 52.9% success rate and an average return of 2.6% over the past year. This rating is provided for informational purposes and is not an investment recommendation.
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 37.5% Potential Upside in Biotech
Rhythm Pharmaceuticals (RYTM) is analyzed as a compelling investment in the biotech sector, specializing in rare neuroendocrine diseases with its flagship product IMCIVREE. The company boasts significant revenue growth and strong analyst ratings, predicting a 37.5% potential upside. Despite current negative earnings and substantial investments in R&D, its strategic product pipeline and partnerships are expected to drive long-term value creation.
(RYTM) and the Role of Price-Sensitive Allocations
This article provides an in-depth analysis of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), highlighting a weak near-term sentiment but strong long-term prospects. It outlines specific AI-generated trading strategies—position, momentum breakout, and risk hedging—along with support and resistance levels across different time horizons. The analysis emphasizes an exceptional risk-reward setup targeting a 13.0% gain with minimal risk.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Brokerages
Rhythm Pharmaceuticals (NASDAQ:RYTM) has received a consensus "Moderate Buy" rating from 18 analysts, with an average 12-month price target of $131.29. Despite missing EPS estimates and having negative net margins and return on equity, the company's revenue slightly exceeded expectations, and several firms recently raised their price targets. Insider selling activity and significant institutional ownership changes were also noted.
What is HC Wainwright's Estimate for RYTM FY2025 Earnings?
HC Wainwright has increased its FY2025 EPS estimate for Rhythm Pharmaceuticals (NASDAQ:RYTM) to ($3.10) per share, an improvement from their previous forecast of ($3.13). The firm maintains a "Buy" rating and a $125 price target, with their FY2025 estimate being significantly more optimistic than the consensus of ($4.32) per share. Despite missing Q3 2025 earnings estimates, several other analysts have also maintained or increased their price targets and ratings for RYTM.
Zacks Research Downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Strong Sell
Zacks Research downgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to a "strong sell" from a "hold" rating. Despite this, the consensus rating from other analysts remains a "Moderate Buy" with an average price target of $131.29. The company reported negative EPS, ROE, and net margin, and insiders sold approximately $1.82 million worth of shares in the last quarter.
Rhythm Pharmaceuticals stock price target raised to $125 from $123 at H.C. Wainwright
H.C. Wainwright has increased its price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) to $125 from $123, maintaining a Buy rating. This adjustment follows the company's preliminary Q4 2025 net product revenues for IMCIVREE, which exceeded forecasts. Rhythm Pharmaceuticals also reported strong full-year 2025 revenue growth and positive preliminary results from a Phase 2 trial of setmelanotide for Prader-Willi syndrome.
Breaking Down Rhythm Pharmaceuticals: 13 Analysts Share Their Views
Thirteen analysts have provided ratings for Rhythm Pharmaceuticals (NASDAQ: RYTM) over the past three months, with the majority offering bullish or somewhat bullish perspectives. The average 12-month price target for RYTM is $137.15, marking a 12.34% increase from the previous average. While the company demonstrates positive revenue growth and strong net margin, its ROE and ROA are below industry averages, and it maintains a conservative debt management approach.
Rhythm Pharmaceuticals stock price target raised to $125 from $123 at H.C. Wainwright
H.C. Wainwright increased its price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) to $125 from $123, maintaining a Buy rating. This adjustment follows Rhythm's announcement of strong preliminary unaudited net product revenues for Q4 and full-year 2025 for IMCIVREE, which exceeded forecasts. The company also reported positive preliminary results from its Phase 2 trial of setmelanotide for Prader-Willi syndrome.
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025
Rhythm Pharmaceuticals (RYTM) recently provided strong preliminary 2025 revenue guidance for its drug IMCIVREE, projecting approximately US$194 million in net product revenue, a 50% increase over 2024. While a popular narrative suggests the stock is 26.9% undervalued with a fair value of US$139, its high P/S ratio of 38.9x, compared to an industry average of 12.1x, indicates significant valuation risk. The company's future growth relies heavily on IMCIVREE's expansion into new indications and age groups.
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025
Rhythm Pharmaceuticals (RYTM) provided strong preliminary 2025 revenue guidance for its drug IMCIVREE, projecting approximately US$194 million, a 50% increase from 2024. Despite recent share price declines, the company has seen strong long-term shareholder returns. Analyst targets suggest the stock is undervalued, though its high P/S ratio indicates potential valuation risk if market sentiment shifts.
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC
Nisa Investment Advisors LLC significantly increased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 956.9% in the third quarter, bringing their total holdings to $1,339,000. Other institutional investors also adjusted their positions in the company. Analyst ratings for RYTM are predominantly positive, with a "Moderate Buy" consensus and an average target price of $130.00, despite recent insider share sales.
SG Americas Securities LLC Buys 13,369 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
SG Americas Securities LLC increased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 216.2% in the third quarter, acquiring an additional 13,369 shares to own a total of 19,554 shares valued at $1,975,000. Other institutional investors also modified their holdings, with significant increases from Alkeon Capital Management LLC and Harbor Capital Advisors Inc. Despite recent insider selling, analysts maintain a "Moderate Buy" rating with an average target price of $130.00 for the company, which specializes in targeted therapies for rare genetic obesity diseases.
Responsive Playbooks and the RYTM Inflection
This article analyzes Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), highlighting a positive near-term sentiment with a mid-channel oscillation pattern. It presents an exceptional 45.7:1 risk-reward setup, targeting a 13.0% gain versus a 0.3% risk. The piece also details specific AI-generated trading strategies for different risk profiles, including position, momentum, and risk-hedging strategies, along with multi-timeframe signal analysis.
What Rhythm Pharmaceuticals (RYTM)'s Strong IMCIVREE Revenue Beat Means For Shareholders
Rhythm Pharmaceuticals reported strong preliminary unaudited 2025 IMCIVREE net product revenues of US$57 million in Q4 and US$194 million for the full year, with the U.S. market remaining central to sales. This better-than-expected revenue trajectory supports IMCIVREE's commercial momentum, but the company still faces continued operating losses and reliance on a single lead asset. The investment narrative hinges on IMCIVREE's sustained demand and upcoming FDA decisions for new indications, with analysts projecting significant revenue and earnings growth by 2028.
What Rhythm Pharmaceuticals (RYTM)'s Strong IMCIVREE Revenue Beat Means For Shareholders
Rhythm Pharmaceuticals reported strong preliminary unaudited IMCIVREE net product revenues for 2025, exceeding expectations, with the majority still coming from the U.S. This revenue strength supports the company's investment narrative, particularly with an upcoming FDA decision for IMCIVREE in acquired hypothalamic obesity, though the company still faces ongoing losses and reliance on a single core drug. The article highlights that analysts project significant revenue and earnings growth by 2028, with a considerable upside to its current price.
